---
schema_version: research-idea-revision-delta.v1
plugin_version: 0.10.0
artifact_id: revision-delta-I01-001-v056-to-v057
workflow_id: RID-SEPSIS-CSM-20260717-001
idea_id: I01-001
version_id: v056-to-v057
path: tests/idea-narrative-forward-0.9.0-preview.3/one-pass-current/direct-final-current-v23/revision-delta-v056-to-v057.md
based_on:
  - artifact_id: idea-dossier-I01-001-v056
    version: v056
    path: tests/idea-narrative-forward-0.9.0-preview.3/one-pass-current/direct-final-current-v22/idea-dossier-v056.md
  - artifact_id: idea-dossier-I01-001-v057
    version: v057
    path: tests/idea-narrative-forward-0.9.0-preview.3/one-pass-current/direct-final-current-v23/idea-dossier-v057.md
  - artifact_id: editorial-repair-writer-brief-I01-001-r130
    version: r130
    path: tests/idea-narrative-forward-0.9.0-preview.3/one-pass-current/direct-final-current-v22/editorial-repair-writer-brief-r130.yaml
  - artifact_id: protected-content-register-I01-001-v056-v008
    version: v008
    path: tests/idea-narrative-forward-0.9.0-preview.3/one-pass-current/direct-final-current-v22/protected-content-register-v008.yaml
source_skill: multi-path-idea-generator
created_round: 130
change_type: editorial_repair_delta
frozen: true
---

# Revision delta: idea-dossier v056 to v057

## Scope and completion

This editorial repair executed only ALA-001 and ALA-002. It changed reader-facing role names and validation labels without changing the study identity, scientific design, dataset roles, splits, access rules, update operations, thresholds, evidence hierarchy, planned status, fallback logic, or claim strength.

| Item | Disposition |
|---|---|
| ALA-001 | Executed across every occurrence that names the overall representation, fitted complex model, representation output, proposed structural relationship, or simple fallback. |
| ALA-002 | Executed across every occurrence that names temporal holdout validation, hospital holdout validation, isolated second-database test data, frozen-model external validation, isolated test results or materials, or later adaptation/refitting. |
| ALA-003 | Omitted: `do_not_repair_reproduce_or_add_testing`. |
| ALA-004 | Omitted: `do_not_repair_reproduce_or_add_testing`. |
| ALA-005 | Omitted: `do_not_repair_reproduce_or_add_testing`. |
| ALA-006 | Omitted: `do_not_repair_reproduce_or_add_testing`. |
| ALA-007 | Omitted: `do_not_repair_reproduce_or_add_testing`. |

## Included action mapping

| Repair item | Operation and revised locators | Text-grounded acceptance evidence | Result |
|---|---|---|---|
| ALA-001 | Replacement across H1; section 1 title, summary, and positioning; structured abstract; section 3 gap and significance; section 4 question, objectives, and hypothesis; sections 5–11 plan, methods, implementation, evidence chains, outputs, and interpretations; sections 12–14 positioning, claim support, assumptions, limitations, and risks. | H1 and Title are identical; the one-sentence summary and primary question directly identify the ICU temporal scope. The overall object is `候选动态表征`; the fitted model is `候选复杂模型`; model-derived output is `潜在状态表征`; proposed edges, signs, lags, dependencies, comparisons, and stability are `待检验结构关系`. Prior knowledge and uncertainty are stated as `受文献和专家先验约束，并报告估计与预测不确定性`. | PASS |
| ALA-002 | Replacement from the structured abstract through objectives, milestones, WP3–WP4, hospital-primary validation, trial mapping, implementation, evidence chains, outputs, interpretations, contribution, claim support, and section 14. | The abstract defines all three validation strata and explicitly states that the second-database test set did not participate in development and that the frozen model receives no recalibration or parameter update. Later text consistently uses `按时间留出的验证`, `按医院留出的验证`, `隔离测试集`, and `冻结模型外部验证`. `仅校准适配`, `仅观测层适配`, and `全模型重拟合` remain separate after primary external validation. | PASS |

## Overlap disposition

ALA-001 was applied first to distinguish the overall representation, fitted model, latent-state output, and proposed structural relationship. ALA-002 was then applied to the resulting text to distinguish validation strata, isolated test data, frozen-model validation, and later update operations. In shared sentences, the ALA-001 scientific subject and ALA-002 validation predicate remain separate. No representation was relabeled as a validation operation, and no validation label was used as a model name.

## ALA-001 all-occurrence inventory

| Source form and v056 locator group | Assigned role | v057 form and locator/disposition |
|---|---|---|
| `脓毒症全病程候选动态系统表征` (H1 and Title, lines 33 and 37) | Overall study representation | Exact first-use description `用于描述重症监护期间脓毒症发病前风险、首次发病、发病后状态及其转移的候选动态表征` at v057 lines 33 and 37. |
| `知识约束、不确定性感知候选动态系统表征` and the corresponding question modifier (summary and primary question, lines 38 and 76) | Prior and uncertainty procedures plus overall representation | Exact functional wording at v057 lines 38 and 76; no old modifier stack retained. |
| `候选表征`, `全病程候选表征`, `候选动态系统表征`, `候选系统表征`, and `最小全病程候选表征` (lines 40, 44–45, 62, 66, 76, 81, 105, 109, 114, 341, 362, 417, 439, 449, and 492) | Overall study representation | `候选动态表征` at the corresponding v057 opening, plan, chain, interpretation, contribution, claim-support, and risk locators. |
| `复杂候选`, `复杂切换或非线性候选`, `当前候选模型`, and other candidate-model uses (lines 46, 89, 107, 117, 129, 134, 150, 246, 250, 255–256, 326–327, 347, 392, 400, 405, 411–412, 461, 467, 469, 481, and 496) | Fitted complex model | `候选复杂模型` at the corresponding v057 model-admission, simulation, implementation, output, interpretation, assumption, limitation, and risk locators. |
| Model-derived candidate state wording (evidence ladder line 428) | Representation output | `潜在状态表征` at v057 line 428. Objective 2 remains the overall `候选动态表征`, not a model output. |
| `候选结构` and other proposed edge/sign/lag/dependency or stability wording (lines 76, 82, 107, 117, 120, 129, 232, 252–257, 327, 329, 332, 346, 378, 400, 411, 414, 429, 438, 478, and 486) | Proposed structural relationship | `待检验结构关系` at the corresponding v057 question, simulation, validation, implementation, evidence, interpretation, positioning, and limitation locators. |
| Prespecified multistate, linear, prediction-only, and other simple fallback routes (lines 107, 117, 129, 134, 246, 250–251, 257, 347, 382, 392, 405, 411, 467, and 496) | Simple fallback | Retained as `简单表征`, `多状态表征`, `线性状态空间模型`, or `仅预测表征`; none is called a complex candidate. |
| Non-core uses `候选访视信息`, `候选共同生理锚点变量集`, and candidate anchor variables (lines 147, 292, and 483) | Not one of the four central roles | Replaced by direct `备选访视信息`, `备选共同生理锚点变量集`, or `备选共同生理锚点变量`; eligibility and evidence status are unchanged. |
| Forbidden residual forms | Residual scan | No occurrence of `复杂候选`, `知识约束、不确定性感知候选动态系统表征`, `候选状态表征`, `候选结构`, or `最小全病程候选表征`. |

## ALA-002 all-occurrence inventory

| Source role and v056 locator group | v057 form and locator/disposition |
|---|---|
| Temporal holdout validation: `时间外` / `时间外验证` (abstract, milestones, success definition, database role, evidence chain, planned outputs; lines 45–46, 108, 118, 155, 352, and 393) | `按时间留出的验证` at the corresponding v057 locators. |
| Hospital holdout validation: `医院外` / `医院外验证` (abstract, milestones, evidence chain, planned outputs; lines 45–46, 108, 352, and 393) | `按医院留出的验证` at the corresponding v057 locators; never used for a prehospital population. |
| Isolated second-database test data: `未触碰最终测试区`, `未触碰测试区`, `未触碰测试资料`, `未触碰外部数据库`, and synonymous final-test data/access wording (lines 45, 82, 89, 99, 106, 108–109, 131, 134, 150, 156, 166, 177, 211, 213, 238, 263, 270–273, 280, 296, 328–329, 359, 393, 398, 405, 417, 429, 450, 459, 469–470, 481, 494, and 496) | `第二数据库中未参与开发的隔离测试集` at first abstract use, then `隔离测试集` or `隔离测试集资料`; access and result unavailability are stated directly. |
| Primary external validation: `未触碰数据库检验`, `未触碰跨数据库检验`, `不更新外部检验`, and `冻结模型的跨数据库检验` (abstract, milestones, success definition, methods, implementation, evidence, outputs, interpretation, contribution, claim support, limitation, and risk locators) | Full first definition at v057 line 45, then `冻结模型外部验证` at lines 46, 48, 109, 120, 122, 134, 150, 275, 280, 296, 329, 360, 402, 412–413, 423, 429, 450, 452, 459, 480, and 494. |
| Isolated test results or materials: `未触碰跨数据库结果`, `未触碰外部结果`, and `未触碰跨数据库资料` (abstract, milestones, work packages, outputs, interpretations, contribution, assumptions, and risks) | `隔离测试集上的外部验证结果` for results and `隔离测试集资料` for data at v057 lines 47, 99, 106, 122, 131, 150, 238, 273, 280, 393, 405, 417, 429, 459, 469–470, 494, and 496. |
| Post-validation operations | `仅校准适配`, `仅观测层适配`, and `全模型重拟合` remain three distinct operations at v057 lines 109, 122, 275–280, 329, 360, 413, 429, and 480; none is absorbed into frozen-model external validation. |
| Forbidden residual forms | No occurrence of `时间外`, `医院外`, `未触碰`, or `不更新外部检验`. |

## Protected-content preservation index

| Protected ID | Revised locator(s) | Item-level preservation evidence |
|---|---|---|
| PCR-001 | Frontmatter > `identity_anchor` | All five machine-facing values are character-for-character unchanged. |
| PCR-002 | Section 4 > Primary research question; Objectives | ICU continuum, four objectives, conditional trial extension, causal boundary, and scientific deliverable remain intact; only role names changed. |
| PCR-003 | Section 4 > Core hypothesis and evidence boundary | Common-variable support, pre-analysis fixation, absolute recovery, misspecification checks, allowed invariants, and noncausal estimand boundary remain unchanged. |
| PCR-004 | Section 7 > Observational target, anchoring, and evidence-qualified interpretation | Study object, patient-time/state-transition unit, clustering, X/Y/A/M/B/S roles, joint distribution, and derived quantities are retained. |
| PCR-005 | Section 7 > Protocol locks for the two primary clinical tasks | Adult cohorts, first stays/onset, history, delayed entry, weighting, mutually exclusive terminations, and censoring rules are unchanged. |
| PCR-006 | Section 7 > Mutually exclusive post-onset state and event system | Twelve-hour assignment, fixed priority, unsortable-time rule, absorbing/terminal states, relapse, and transitions are unchanged. |
| PCR-007 | Section 6 > Variable roles | Physiology, treatment, measurement, label-only, and baseline roles and all separation/leakage prohibitions are retained. |
| PCR-008 | Section 6 > Public intensive-care database roles and support audit | MIMIC/eICU roles, backup rule, shared-concept audit, and exploratory database-specific information remain unchanged. |
| PCR-009 | Section 6 > Public intensive-care database roles and support audit table | Access and support audits; 20/10 event rules; anchor-density, hospital/patient coverage, dimension/state limits, and time-grid rules are unchanged. |
| PCR-010 | Section 6 > Current resource and result status | Verified database existence versus unverified access/audits, absence of model/results, and bounded closest-work confidence remain unchanged. |
| PCR-011 | Section 6 > Local randomized-trial evidence status | EXIT-SEP and XBJ-SCAP counts, missingness, unavailable fields, D-dimer uncertainty, and derivative-evidence limits are unchanged. |
| PCR-012 | Section 6 > Current resource and result status trial rows | Authorization, original-source semantics, timing, anchors, units, and data-holder confirmation requirements remain unchanged. |
| PCR-013 | Section 14 > Feasibility and resources | Required roles, unverified commitments, scope caps, and excluded animal/trial/causal/control work remain unchanged. |
| PCR-014 | Section 5 > Work packages and minimum route | Full precedence, simple fallbacks, backup/stop logic, stage I–II minimum, and subordinate stage III remain unchanged. |
| PCR-015 | Section 5 > Conjunctive minimum success definition | Every data, simulation, primary-task, leakage, hospital, frozen-validation, alignment, sign, adaptation, and stage dependency remains unchanged. |
| PCR-016 | Section 7 > Protocol locks > primary pre-onset task | Population, landmarks, horizon, cumulative incidence, metrics, bootstrap, and all fixed gates remain unchanged. |
| PCR-017 | Section 7 > Protocol locks > primary post-onset task | Day-7 favorable occupancy, multistate/Aalen–Johansen methods, sensitivity, metrics, bootstrap, and gates remain unchanged. |
| PCR-018 | Section 7 > Protocol locks > event and availability clocks | Antibiotic/culture pairing, baseline and rolling SOFA rules, onset/availability timing, and two sensitivity labels remain unchanged. |
| PCR-019 | Section 7 > Mutually exclusive post-onset state and event system | Recovery, deterioration, support escalation, exit, transfer, and death definitions and availability times remain unchanged. |
| PCR-020 | Section 7 > Observational target, anchoring, and evidence-qualified interpretation | Two anchors/dimension, loading and sparsity constraints, dimension/state/lag caps, seed alignment, and interpretable targets remain unchanged. |
| PCR-021 | Section 7 > Observational target > missingness and action support | Missingness models, five-shift grid, tipping analysis, action prevalence, effective-sample threshold, and no-treatment-effect rule remain unchanged. |
| PCR-022 | Section 7 > Absolute simulation and semi-synthetic recovery criteria | Months 7–10, 1,000 repeats/MCSE rule, generator families, and crossed scenario factors remain unchanged. |
| PCR-023 | Section 7 > Absolute simulation and semi-synthetic recovery criteria > continuous branch | X matrices, evaluation rows, canonical correlations, zero handling, no result-driven deletion, interval formula, and 0.80 rule remain unchanged. |
| PCR-024 | Section 7 > recovery criteria table | Every discrete/transition/sign/edge/zero-edge/misspecification/calibration threshold and failure action remains unchanged. |
| PCR-025 | Section 7 > Hospital-primary cross-database validation | Seeded 30/70 hospital split, patient exclusions, pre-result reporting, bipartite sensitivity, support thresholds, backup, and claim limits remain unchanged. |
| PCR-026 | Section 7 > Hospital-primary cross-database validation > four operations | Frozen validation, calibration-only adaptation, observation-layer-only adaptation, full refit, order, test-data restrictions, and failure interpretation remain unchanged. |
| PCR-027 | Section 7 > Trial mapping and independent analysis > shared prerequisites | Stage-II success, authorization, original semantics, branch-specific mapping requirements, trial separation, and subordinate timing remain unchanged. |
| PCR-028 | Section 7 > mapped ordered-visit outcome and fidelity | Anchor eligibility, frozen standardization/SVD, sign rule, eICU fidelity thresholds, blinded-trial thresholds, and ineligibility rules remain unchanged. |
| PCR-029 | Section 7 > stratified standardized probability index | Complete estimand, strata and pooled weights, tie handling, direction, interval/testing structure, secondary quantities, and trial separation remain unchanged. |
| PCR-030 | Section 7 > independent SOFA branch; semantic stop | Mutually exclusive fallback branch, its independent endpoint, and full semantic stopping rule remain unchanged. |
| PCR-031 | Section 7 > EXIT-SEP/XBJ-SCAP table | Analysis populations, visits, missing-data methods, bounds, unavailable fields, Holm family, interactions, and no pseudo-trajectories remain unchanged. |
| PCR-032 | Section 7 > Secondary representation diagnostics | Pseudo-mask and future-trajectory metrics, stratification, and inability to change primary decisions remain unchanged. |
| PCR-033 | Sections 7 and 10 | Full stage-II evidence list, unit tests, baselines, simulations, controls, four operations, conjunct table, and trial-specific evidence remain unchanged. |
| PCR-034 | Section 11 > Falsification and stop criteria > clocks/data support | Leakage failure, correction/deletion, external-test block, support failure, fallback, and stop actions remain unchanged. |
| PCR-035 | Section 11 > Falsification and stop criteria > recovery/missingness/external result | Recovery, coverage, zero-edge, misspecification, missingness, action support, frozen-validation failure, and adaptation interpretation remain unchanged. |
| PCR-036 | Section 11 > Falsification and stop criteria > trial criteria | Mapping/fidelity stops, independent-SOFA eligibility, semantic stop, discordance, imprecision, and no subgroup repair remain unchanged. |
| PCR-037 | Section 11 > Falsification and stop criteria > time | Month-12, month-20, and month-24 consequences remain unchanged. |
| PCR-038 | Section 14 > Risks, alternatives, and stop conditions | Database/support, staffing, isolation, cross-hospital, trial, novelty, and non-relaxation contingencies remain unchanged. |
| PCR-039 | Sections 1–2 | Candidate/planned status, expected outputs, conditional integration/validation/resource contribution, and subordinate trial extension remain unchanged. |
| PCR-040 | Section 12 > Contribution and evidence ladder | Evidence escalation from traceability to state/task, frozen validation, trial-only difference, and absent causal/application evidence remains unchanged. |
| PCR-041 | Section 12 > Verified representative closest-work comparison | Component precedents, bounded-search date/confidence, conditional integration/validation position, and no novelty/first claim remain unchanged. |
| PCR-042 | Section 11 > Interpretation matrix | Every simple-model, simulation, frozen-validation, adaptation, task, trial, and full-conjunction interpretation boundary remains unchanged. |
| PCR-043 | Section 7 trial methods; section 9 trial evidence chain | Trial outputs remain separate, secondary, conditional, non-pooled, non-repairing, and limited to within-trial ordered outcomes. |
| PCR-044 | Section 14 > Working assumptions > continuous recovery | Exact continuous-recovery definition, owners, deadline, fallback consequence, and affected component remain unchanged. |
| PCR-045 | Section 14 > Working assumptions > trial probability index | Unique estimand, tie handling, verified strata/weights, owner confirmation, deadline, and stop consequence remain unchanged. |
| PCR-046 | Section 14 > Working assumptions > clinical-to-simulation mapping | Month-7 information rule, fixed generators/criteria, external-result exclusion, and unresolved consequence remain unchanged. |
| PCR-047 | Section 14 > Working assumptions > multicategory calibration | Month-6 estimator/interval/registration decision, fixed metrics and thresholds, no-relaxation rule, and stop consequence remain unchanged. |
| PCR-048 | Section 14 > Limitations 1 | Resource, access, team, extract, audit, and official-scale boundaries remain complete and unchanged. |
| PCR-049 | Section 14 > Limitations 2 | Label, clock, timestamp, dual-use, measurement, repeat-admission, split-processing, and leakage boundary remains complete and unchanged. |
| PCR-050 | Section 14 > Limitations 3 | Recoverability, allowed reparameterization, simulation scope, required evidence, and failed-state/edge consequences remain complete and unchanged. |
| PCR-051 | Section 14 > Limitations 4 | Missingness sensitivity and low-action-overlap inference boundary remains complete and unchanged. |
| PCR-052 | Section 14 > Limitations 5 | Database differences, interface absence, primary frozen validation, separate adaptation/refit roles, and failed-result rule remain complete and unchanged. |
| PCR-053 | Section 14 > Limitations 6 | Twenty-four-month boundary, month-12/20/24 consequences, subordinate stage III, and no later repair remain complete and unchanged. |
| PCR-054 | Section 14 > Limitations 7 | Conditional trial data, original-source requirements, sparse visits, population/field differences, and no pooled/pseudo-continuous inference remain complete and unchanged. |
| PCR-055 | Section 14 > Limitations 8 | WBC/CRP candidate status, D-dimer uncertainty, absent fidelity results, mapped outcome scope, and independent-SOFA boundary remain complete and unchanged. |
| PCR-056 | Section 14 > Limitations 9 | Non-systematic search coverage and low-to-moderate full-combination confidence remain complete and unchanged. |
| PCR-057 | Section 14 > Limitations 10 | 2026 guideline/regulatory caution and no unconditional international promotion remain complete and unchanged. |
| PCR-058 | Section 14 > Limitations 11 | All prohibited causal, policy, mechanism, mediation, control, digital-twin, validation, tool, platform, promotion, and subgroup-repair claims remain complete and unchanged. |
| PCR-059 | Section 5 > 24-month milestones | Role signatures, unverified commitments, custodian access rule, and no post-month-20 result-driven modification remain unchanged. |
| PCR-060 | Section 14 > Working assumptions closing qualification | Screening-minimum boundary, empirical support requirements, fixed decision times/information, and no invented post hoc values remain unchanged. |
| PCR-061 | Section 14 > Limitations 11 | Causal-network/effect/policy/mechanism/mediation/control/digital-twin claim classes remain explicitly unsupported. |
| PCR-062 | Sections 12 and 14 > evidence ladder; Limitations 11 | No already-validated model, decision tool, drug platform, effectiveness, or unconditional promotion claim; missing evidence requirements remain explicit. |
| PCR-063 | Section 12 > Verified representative closest-work comparison | No new-algorithm/global-first/absence/patent claim; stronger novelty requires new searches; bounded conditional position remains explicit. |
| PCR-064 | Sections 7 and 11 > trial methods; interpretation matrix | Trial differences do not validate latent dynamics, edges, external structure, or the whole system; no pooled mechanism or subgroup repair remains explicit. |

Preservation coverage: **64/64 PASS**.

## Machine identity comparison

| Field | Register v008 and dossier v057 verbatim value | Result |
|---|---|---|
| `primary_research_question` | `can a knowledge-constrained, uncertainty-aware dynamic system representation of ICU patients cover the sepsis-centered pre-onset, onset, post-onset, and outcome continuum, demonstrate cross-database state/structure validity, and then test limited randomized intervention perturbations without conflating prediction with causality?` | Identical |
| `primary_objective` | `construct and validate the sepsis complex-system model, with stage II completed within 24 months.` | Identical |
| `study_object` | `the longitudinal sepsis-centered ICU patient system, including comparable at-risk non-onset intervals and post-onset trajectories.` | Identical |
| `core_data_or_evidence_base` | `literature/expert priors; longitudinal public ICU data; conditionally available EXIT-SEP and XBJ-SCAP individual-level RCT data.` | Identical |
| `primary_unit_of_inference` | `patient-time state and state transition, with patient and hospital clustering respected.` | Identical |

Identity coverage: **5/5 PASS**.

## Limitation authority check

The eleven complete limitation families remain once, under section 14 > `Limitations and boundary conditions`, in the original order:

1. Resources, access, and team status
2. Labels, clocks, and leakage
3. State recoverability and structural scope
4. Nonrandom missingness and low action overlap
5. Cross-database evidence
6. Time and delivery boundary
7. Trial data and semantics
8. Common physiological anchor variables and observation mapping
9. Closest-work uncertainty
10. Regulatory applicability
11. Complete prohibited claims

Other sections retain only their distinct scientific methods, eligibility, result-dependent interpretation, falsification, access, or operational-governance functions; none restates a complete limitation family. Limitation authority coverage: **11/11 PASS**.

## Deterministic lint receipt and advisory dispositions

The required command exited successfully and reported `OK` for `idea-dossier-v057.md` with expected plugin version `0.10.0`. It emitted eight advisory review candidates and no errors.

| Advisory locator | Flagged wording | Semantic disposition |
|---|---|---|
| Dossier line 45 | `锚点观测值`, `锚点预测值` | Retained as legitimate scientific measurement and prediction roles; both are defined immediately in the same sentence. |
| Dossier line 240 | `X_b`, `d_b`, `r_b`, `r_b=0` | Retained as locally defined mathematical objects and the prespecified failure-handling value for continuous-state recovery. |
| Dossier line 242 | `s_r` in the interval formula | Retained as mathematical notation; its meaning is stated at line 244. |
| Dossier line 244 | `r_b`, `s_r` | Retained because the sentence explicitly defines them as the repeat statistic and its sample standard deviation. |
| Dossier line 300 | `Y_0`, `Y_1` | Retained as the control- and trial-arm actual-visit ordered outcomes, defined immediately before the formula. |
| Dossier line 302 | `Y_0`, `Y_1`, `omega_s`, summation notation | Retained as the displayed primary estimand; every object is defined in the adjacent lines. |
| Dossier line 304 | `omega_s` and tie wording | Retained because pooled-arm stratum weights, favorable direction, and half-credit ties are explicitly defined. |
| Dossier line 467 | `记为 0` | Retained as the complete prespecified failure consequence for dimension/rank/algorithm failure, not an implementation shorthand. |

Advisory semantic disposition: **8/8 complete**.

## Final conformance

- Included repairs: **2/2 PASS**.
- Omitted minor findings: **5/5 remained unexecuted**.
- Forbidden residual forms: **none**.
- Protected items: **64/64 PASS**.
- Machine identity anchors: **5/5 identical**.
- Complete limitation families at section-14 authority: **11/11 PASS**.
- Dossier state: `frozen: true`.
- Delta state: `frozen: true`.
